title: Effects of various pharmacological agents on isolated human bronchial and pulmonary arterial and venous muscle preparations contracted by leukotriene D4.
abstract: The response of isolated human bronchial muscle preparations to leukotriene D4 (LTD4, 0.1 microM; 0.22 +/- 0.03 g/mm2) was similar to that of histamine (50 microM; 0.21 +/- 0.02 g/mm2). Isolated pulmonary venous preparations also contracted to these same concentrations of both agonists (LTD4, 0.32 +/- 0.19 g/mm2; and histamine, 0.36 +/- 0.07 g/mm2). However, pulmonary arterial preparations responded to histamine (50 microM, 0.59 +/- 0.10 g/mm2) but exhibited a reduced response to LTD4 (0.3 microM, 0.06 +/- 0.01 g/mm2). Bronchial and pulmonary venous muscle preparations from the human lung had the same sensitivities to LTD4 (pD2 values: bronchus, 7.95 +/- 0.08 and vein, 7.76 +/- 0.07). When bronchial or pulmonary venous muscle preparations were incubated for 30 min with either diltiazem (10 microM), indomethacin (1.7 microM) or L-cysteine (3 microM), the LTD4 cumulative concentration-effect curves following these drug treatments were similar to controls. However, FPL-55712 (10 microM) significantly shifted the LTD4 concentration-effect curves produced in bronchial preparations to the right. In isolated pulmonary arterial preparations none of these drug treatments enhanced the LTD4 response. These results show that isolated human pulmonary arterial preparations are less responsive to LTD4 than bronchial or venous preparations. In addition, the data obtained subsequent to the various drug treatments indirectly suggest that the LTD4 contraction is not modified by a calcium channel blocker or by inhibition of the endogenous products of the cyclooxygenase pathway.
authors.affiliation: Laboratoires Yves Rocher, Paris, France.
authors.forename: B
authors.initials: B
authors.lastname: Bourdillat
authors.forename: I
authors.initials: I
authors.lastname: Haye-Legrand
authors.forename: C
authors.initials: C
authors.lastname: Labat
authors.forename: B
authors.initials: B
authors.lastname: Raffestin
authors.forename: X
authors.initials: X
authors.lastname: Norel
authors.forename: J
authors.initials: J
authors.lastname: Benveniste
authors.forename: C
authors.initials: C
authors.lastname: Brink
mesh_terms: D001158:Arteries / Q000187:drug effects; D001980:Bronchi / Q000098:blood supply*; D002217:Carbachol / Q000494:pharmacology; D002867:Chromones / Q000494:pharmacology; D003545:Cysteine / Q000494:pharmacology; D004110:Diltiazem / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006632:Histamine / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D008168:Lung / Q000098:blood supply*; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D013189:SRS-A / Q000037:antagonists & inhibitors / Q000502:physiology*; D014680:Veins / Q000187:drug effects
chemical_list: D002867:Chromones; D013189:SRS-A; D006632:Histamine; C006312:FPL 55712; D002217:Carbachol; D004110:Diltiazem; D003545:Cysteine; D007213:Indomethacin